Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib plus bevacizumab for EGFR-mutant NSCLC with brain metastases (real-world, single-arm, phase 4)
ChiCTR2500101260Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib and bevacizumab in non-small cell lung cancer (NSCLC), EGFR-mutated non-small cell lung cancer and brain metastases, sponsored by Henan Cancer Hospital. Primary endpoint: Intracranial progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
imatinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2500101260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101260.